Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: The CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group

D. Lorusso, G. Ferrandina, S. Pignata, M. Ludovisi, R. ViganĂ², S. Scalone, P. Scollo, E. Breda, A. Pietragalla, G. Scambia

Research output: Contribution to journal › Article

Fingerprint Dive into the research topics of 'Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: The CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group'. Together they form a unique fingerprint.

Medicine & Life Sciences